Compare IOL Chemicals with Similar Stocks
Dashboard
Poor long term growth as Net Sales has grown by an annual rate of 0.38% and Operating profit at 7.22% over the last 5 years
With ROE of 6.6, it has a Expensive valuation with a 1.2 Price to Book Value
Despite the size of the company, domestic mutual funds hold only 0.04% of the company
Stock DNA
Pharmaceuticals & Biotechnology
INR 2,156 Cr (Small Cap)
17.00
36
1.40%
-0.01
6.62%
1.20
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Feb-17-2026
Risk Adjusted Returns v/s 
Returns Beta
News

IOL Chemicals & Pharmaceuticals Ltd Surges 7.81% to Day's High of Rs 78.14 — Outperforms Sector by 7.2 Percentage Points
The Sensex declined by 1.02% on 24 Mar 2026, yet IOL Chemicals & Pharmaceuticals Ltd surged 7.81%, reaching an intraday high of Rs 78.14. This 7.2 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.
Read full news article
IOL Chemicals & Pharmaceuticals Ltd Faces Bearish Technical Shift Amid Market Volatility
IOL Chemicals & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent downgrade from Hold to Sell by MarketsMOJO, coupled with deteriorating moving averages and bearish MACD readings, suggests increasing downside pressure amid a challenging market environment.
Read full news article
IOL Chemicals & Pharmaceuticals Ltd Sees Mixed Technical Signals Amid Mildly Bearish Momentum
IOL Chemicals & Pharmaceuticals Ltd has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a recent uptick in price, key technical indicators such as MACD and moving averages continue to signal caution, reflecting a complex landscape for investors in this small-cap pharmaceutical player.
Read full news article Announcements 
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
20-Mar-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for NCVI Enterprises Ltd & PACs
Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015
20-Mar-2026 | Source : BSEDisclosure under SEBI (PIT) Regulations
Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015
19-Mar-2026 | Source : BSEDisclosure under SEBI (PIT) Regulations
Corporate Actions 
No Upcoming Board Meetings
IOL Chemicals & Pharmaceuticals Ltd has declared 50% dividend, ex-date: 17 Feb 26
IOL Chemicals & Pharmaceuticals Ltd has announced 2:10 stock split, ex-date: 11 Mar 25
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 6 Schemes (0.02%)
Held by 59 FIIs (2.08%)
Maya Devi Polycot Limited (21.54%)
Vasudeva Commercials Limited (4%)
30.51%
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 2.27% vs 2.87% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -31.33% vs -11.67% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 8.86% vs -7.25% in Sep 2024
Growth in half year ended Sep 2025 is 30.09% vs -41.34% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 9.55% vs -4.75% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 21.29% vs -34.79% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -2.51% vs -3.80% in Mar 2024
YoY Growth in year ended Mar 2025 is -24.82% vs -3.39% in Mar 2024






